Co-administration of small-molecule HSP27 inhibitors, such as J2, should be considered because they may improve cancer-targeted therapy in NSCLC by pAKT inhibition, which is a critical factor for Gef resistance and may provide an important step forward given the limitations of existing treatment options. The gene discussed is HSPB1; the disease is cancer.